Forman, Rebecca ORCID: 0000-0002-0124-9997, Shah, Soleil, Jeurissen, Patrick, Jit, Mark and Mossialos, Elias ORCID: 0000-0001-8664-9297 (2021) COVID-19 vaccine challenges: what have we learned so far and what remains to be done? Health Policy, 125 (5). 553 - 567. ISSN 0168-8510
Text (1-s2.0-S0168851021000853-main)
- Published Version
Available under License Creative Commons Attribution. Download (811kB) |
Abstract
Developing and distributing a safe and effective SARS-CoV-2 (COVID-19) vaccine has garnered immense global interest. Less than a year after COVID-19 was declared a pandemic, several vaccine candidates had received emergency use authorization across a range of countries. Despite this scientific breakthrough, the journey from vaccine discovery to global herd immunity against COVID-19 continues to present significant policy challenges that require a collaborative, global response. We offer a framework for understanding remaining and new policy challenges for successful global vaccine campaigns against COVID-19 as well as potential solutions to address them. Decision-makers must be aware of these challenges and strategize solutions that can be implemented at scale. These include challenges around maintaining R&D incentives, running clinical trials, authorizations, post-market surveillance, manufacturing and supply, global dissemination, allocation, uptake, and clinical system adaption. Alongside these challenges, financial and ethical concerns must also be addressed.
Item Type: | Article |
---|---|
Official URL: | https://www.sciencedirect.com/journal/health-polic... |
Additional Information: | © 2021 The Authors |
Divisions: | Health Policy |
Subjects: | R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine H Social Sciences > HV Social pathology. Social and public welfare. Criminology |
Date Deposited: | 21 May 2021 23:15 |
Last Modified: | 05 Oct 2024 00:12 |
URI: | http://eprints.lse.ac.uk/id/eprint/110533 |
Actions (login required)
View Item |